STAAR Surgical Company (STAA)
Return on equity (ROE)
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | -20 | 21,347 | 39,665 | 27,511 | 5,913 |
| Total stockholders’ equity | US$ in thousands | 397,335 | 385,954 | 332,442 | 258,558 | 197,222 |
| ROE | -0.01% | 5.53% | 11.93% | 10.64% | 3.00% |
December 31, 2024 calculation
ROE = Net income ÷ Total stockholders’ equity
= $-20K ÷ $397,335K
= -0.01%
STAAR Surgical Company's return on equity (ROE) has exhibited fluctuations over the past five years. In December 2020, the ROE was at a low of 3.00%, indicating a relatively lower profitability compared to the subsequent years. The company showed significant improvement in December 2021, with ROE jumping to 10.64%, suggesting enhanced efficiency in generating profits relative to shareholder equity.
By December 2022, STAAR Surgical Company further increased its ROE to 11.93%, reflecting continued growth in profitability and efficient utilization of equity investments. However, in December 2023, the ROE declined to 5.53%, indicating a moderation in profit generation compared to the previous year.
The most recent data point, December 2024, shows that the company's ROE dropped slightly to -0.01%, signifying a negative return on equity. This decline may raise concerns about the company's ability to generate profits relative to shareholders' investments.
In summary, STAAR Surgical Company's ROE performance has been mixed over the past five years, with notable improvements in 2021 and 2022, but a concerning decline in 2024. Further analysis of the underlying factors impacting profitability and equity management would be necessary to better understand the dynamics driving these fluctuations.
Peer comparison
Dec 31, 2024